Fonlupt P, Croset M, Lagarde M
INSERM U205, Chimie Biologique-INSA B406, Villeurbanne, France.
Thromb Res. 1991 Jul 15;63(2):239-48. doi: 10.1016/0049-3848(91)90287-7.
12(S)-hydroxy-5,8,10,14-eicosatetraenoic acid (12-HETE), the end-lipoxygenase product of arachidonic acid in platelets has been previously shown to prevent PGH2/TxA2-induced aggregation. From the present study, we show that 12-HETE inhibits the binding of [125I]-PTA-OH, a thromboxane antagonist, to platelet membranes with an IC50 of 8 microM. This value is in accordance with previously reported 12-HETE concentrations required to prevent the aggregation induced by TxA2 mimetics, the methano analogues of PGH2, U44069 and U46619. When [3H]-U44069 was used as a thromboxane agonist to label intact platelets, 12-HETE also inhibited its binding. We conclude that part of the inhibitory effect of 12-HETE on PGH2/TxA2-induced aggregation might be the result of interacting with PGH2/TxA2 receptor sites.
12(S)-羟基-5,8,10,14-二十碳四烯酸(12-HETE)是血小板中花生四烯酸的终末脂氧合酶产物,先前已证明其可阻止PGH2/TxA2诱导的聚集。在本研究中,我们发现12-HETE抑制血栓素拮抗剂[125I]-PTA-OH与血小板膜的结合,IC50为8微摩尔。该值与先前报道的防止TxA2模拟物(PGH2的甲烷类似物U44069和U46619)诱导聚集所需的12-HETE浓度一致。当使用[3H]-U44069作为血栓素激动剂标记完整血小板时,12-HETE也抑制其结合。我们得出结论,12-HETE对PGH2/TxA2诱导聚集的部分抑制作用可能是与PGH2/TxA2受体位点相互作用的结果。